Oculis (OCS) H.C. Wainwright 26th Annual Global Investment Conference summary

Conference overview

• Over 600 companies presented across life sciences, fintech, technology, clean tech, and more, with sector tracks and panels available live and for streaming.

• H.C. Wainwright covers 636 companies with 24 senior analysts, offering corporate finance and strategic advisory services.

Clinical pipeline and recent achievements

• Achieved Nasdaq listing in 2023 and Nasdaq Iceland listing in 2024, reflecting strong investor interest.

• OCS-01, a topical eye drop for DME, showed positive phase III stage one results, matching efficacy of anti-VEGF injections.

• OCS-02, a TNF blocker for dry eye, demonstrated strong efficacy, rapid onset, and a precision medicine approach using the TNFR1 biomarker.

• OCS-05, a neuroprotective agent, is in the ACUITY trial for acute optic neuritis, with Q4 readout expected.

Market opportunities and unmet needs

• DME market has a large untreated population; OCS-01 could expand treatment to early-stage and anti-VEGF non-responders.

• Dry eye market is expected to double in 5–10 years, with 87% of patients unsatisfied with current treatments.

• OCS-02's biomarker-driven approach could enable the first precision medicine in dry eye, improving outcomes and patient satisfaction.